In MDA-MB-231 breast cancer cells, Lcn2 inhibition was shown to promote erastin-mediated ferroptosis, leading to reduced tumor cell proliferation, metastasis, and enhanced chemosensitivity to cisplatin (70). This evidence concerns the gene LCN2 and breast carcinoma.